Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01514682 · ClinicalTrials.gov registry record · NA
Anti-Inflammatory Treatment of Schizophrenia
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01514682 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 50 participants.
The verdict
NCT01514682, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Despite current antipsychotic treatment, the majority of people with schizophrenia continue to exhibit persistent positive and negative symptoms and cognitive impairments. An alternative approach to the use of psychotropic agents for the treatment of persistent symptoms is the use of anti-inflammatory agents to reverse the pro-inflammatory state hypothesized to underlie the symptom and sign manifestations of the illness. The investigators primary hypothesis is that add-on anti-inflammatory combination therapy will have significant beneficial effects on persistent positive symptoms and cognitive impairments. The investigators secondary hypotheses are: 1. add-on anti-inflammatory combination therapy will be associated with improvements in depressive and negative symptoms and a reduction in pro-inflammatory cytokines 2. add-on anti-inflammatory combination therapy compared to placebo will not be associated with elevated adverse risk.
Interventions
- DRUG Placebo
- DRUG Anti-inflammatory Combination Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-04-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01514682
The ClinicalTrials.gov registry entry for NCT01514682 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01514682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01514682 about?
NCT01514682 is a clinical study titled "Anti-Inflammatory Treatment of Schizophrenia". Despite current antipsychotic treatment, the majority of people with schizophrenia continue to exhibit persistent positive and negative symptoms and cognitive impairments. An alternative approach to the use of psychotropic agents for the treatment of persistent symptoms is the use of anti-inflammato...
What is the current status of trial NCT01514682?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2012-06. Estimated completion is 2017-04-17.
What interventions are being tested in trial NCT01514682?
The interventions under investigation include: Placebo (DRUG), Anti-inflammatory Combination Therapy (DRUG).
Who is sponsoring clinical trial NCT01514682?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.